C-Rad AB Class B (CRAD.B) AI Stock Analysis

• Market Cap: kr1.09B
• Dividend Yield: N/A
• Average Volume (3M): 58.03K
• Price to Earnings (P/E): 46.7
• Beta (1Y): 0.40
• Revenue Growth: -5.80%
• EPS Growth: -65.99%
• Country: SE
• Employees: 99
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.38
• Shares Outstanding: 32,904,050
• 10 Day Avg. Volume: 15,927
• 30 Day Avg. Volume: 58,029
• PEG Ratio: 0.30
• Price to Book (P/B): 3.12
• Price to Sales (P/S): 2.16
• P/FCF Ratio: 34.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: kr35.00 ▲(9.72% Upside)

C-Rad AB Class B's overall stock score is primarily driven by its strong financial performance, particularly in cash flow management and a robust balance sheet. However, the technical analysis indicates weak momentum, and the high P/E ratio suggests potential overvaluation, which tempers the overall score.

Positive Factors

Cash Flow Management

Strong cash flow management enhances the company's ability to invest in growth opportunities and service debt, supporting long-term stability.

Balance Sheet Health

A strong balance sheet with low leverage provides financial flexibility and reduces risk, supporting sustainable growth.

Revenue Model

A diversified revenue model ensures stable income streams and reduces dependency on single revenue sources, aiding long-term resilience.

Negative Factors

Profitability Margins

Declining profitability margins can impact overall financial performance, limiting the company's ability to reinvest in growth.

Revenue Growth

Negative revenue growth suggests challenges in market expansion or product adoption, potentially affecting future earnings.

EPS Growth

A sharp decline in EPS growth can signal operational challenges and may affect investor confidence and future capital raising.

C-Rad AB Class B Business Overview & Revenue Model

Company Description

C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. The company operates through two segments, Positioning and Imaging. Its products include Sentinel 4D CT, a laser-based optical surface scanning system; Catalyst, a 4D surface image guided radiation therapy (SIGRT) solution; Catalyst HD, an SIGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst+, an SIGRT solution for high precision patient positioning, intra-fraction motion management, and respiratory gating; and Catalyst+ HD, a solution for high precision patient positioning, intra-fraction motion management, and respiratory gating for conventional and stereotactic treatment delivery. The company's products also comprise Catalyst Tomo, an enhanced positioning solution for tomotherapy; Catalyst PT, a real-time tracking solution for particle therapy; Cyrpa laser positioning products; cAccessory, which automates the registration and validation of treatment accessories; and cPatient that automates patient identity validation without the need for contact between patients and devices. In addition, it offers installation, application training, and aftersales services. C-Rad AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.

How the Company Makes Money

C-Rad AB generates revenue primarily through the sale of its medical devices and software solutions to hospitals and healthcare facilities specializing in oncology treatment. The company has a diversified revenue model that includes direct sales, recurring revenue from service contracts, and maintenance agreements for its products. Key revenue streams include the sale of hardware systems such as the C-RAD Catalyst and Sentinel systems, as well as software licenses for their advanced imaging and treatment planning tools. Additionally, C-Rad benefits from strategic partnerships with major players in the healthcare industry, which can enhance market access and provide opportunities for collaborative product development. The company's focus on innovation and quality, combined with the growing demand for precision medicine in cancer treatment, positions it to capture significant market share and drive future growth.

C-Rad AB Class B Financial Statement Overview

Summary

C-Rad AB Class B demonstrates strong financial performance with consistent revenue growth, a solid balance sheet with low leverage, and impressive cash flow management. Despite a slight decline in profitability margins, the company's robust cash generation and low debt-to-equity ratio provide a stable financial foundation.

Income Statement

C-Rad AB Class B has shown consistent revenue growth with a TTM (Trailing-Twelve-Months) increase of 2.72%. The company maintains a solid gross profit margin of 56.42% and a net profit margin of 5.79% in the TTM. However, these margins have decreased compared to the previous year, indicating potential pressure on profitability. The EBIT and EBITDA margins are healthy, reflecting efficient operational management.

Balance Sheet

The company exhibits a strong balance sheet with a low debt-to-equity ratio of 0.03, indicating minimal leverage and financial risk. The return on equity (ROE) is 7.90% in the TTM, which is a decline from the previous year, suggesting a decrease in profitability relative to equity. The equity ratio of 71.41% highlights a robust capital structure with significant equity backing.

Cash Flow

C-Rad AB Class B demonstrates impressive cash flow management with a substantial free cash flow growth rate of 79.85% in the TTM. The operating cash flow to net income ratio is 0.34, and the free cash flow to net income ratio is 1.06, indicating strong cash generation relative to earnings. This positions the company well for future investments and debt servicing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	457.70M	469.00M	424.62M	301.33M	261.15M	221.63M
Gross Profit	253.30M	323.00M	287.21M	205.30M	170.23M	136.89M
EBITDA	71.10M	83.91M	48.90M	27.35M	45.71M	26.15M
Net Income	23.30M	56.45M	35.53M	7.48M	25.10M	14.37M
Balance Sheet
Total Assets	497.80M	489.36M	405.54M	339.17M	306.71M	270.52M
Cash, Cash Equivalents and Short-Term Investments	172.90M	150.90M	129.36M	121.90M	122.42M	108.05M
Total Debt	9.20M	9.00M	1.75M	4.08M	6.37M	7.44M
Total Liabilities	142.30M	164.37M	134.36M	96.63M	75.62M	70.73M
Stockholders Equity	355.50M	325.00M	271.18M	242.54M	231.09M	199.79M
Cash Flow
Free Cash Flow	80.41M	29.21M	16.45M	-1.53M	12.37M	11.66M
Operating Cash Flow	83.68M	30.08M	33.38M	9.69M	18.17M	18.45M
Investing Cash Flow	-17.50M	-6.67M	-16.93M	-11.22M	-5.80M	-6.78M
Financing Cash Flow	-3.00M	-7.04M	-5.69M	-2.38M	1.04M	68.01M

C-Rad AB Class B Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 31.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CRAD.B, the sentiment is Positive. The current price of 31.9 is above the 20-day moving average (MA) of 31.71, below the 50-day MA of 32.61, and below the 200-day MA of 32.48, indicating a neutral trend. The MACD of -0.12 indicates Negative momentum. The RSI at 53.08 is Neutral, neither overbought nor oversold. The STOCH value of 67.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CRAD.B.

C-Rad AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	66 Neutral	kr1.09B	46.67	6.93%	―	-5.80%	-65.99%
PAX	52 Neutral	kr1.27B	200.52	1.41%	―	21.71%	-80.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INTEG.B	48 Neutral	kr275.75M	-7.39	-18.55%	―	0.62%	-82.70%
SEDANA	48 Neutral	kr983.44M	-24.19	-4.42%	―	13.48%	28.98%
BACTI.B	46 Neutral	kr613.27M	-28.83	-6.81%	―	-8.10%	62.08%
SEZI	43 Neutral	kr806.51M	-5.92	-36.55%	―	62.24%	21.16%

C-Rad AB Class B Corporate Events

C-RAD AB Announces Share Repurchase Program to Optimize Capital Structure

C-RAD AB has announced a decision to repurchase up to 597,000 of its own class B shares, valued at a maximum of SEK 20 million, as part of a strategy to optimize its capital structure. This move, authorized by the 2025 Annual General Meeting, aims to reduce share capital by canceling the repurchased shares, potentially impacting the company’s financial targets and shareholder returns.

The most recent analyst rating on ($SE:CRAD.B) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on C-Rad AB Class B stock, see the SE:CRAD.B Stock Forecast page.

C-RAD AB Reports Strong Q3 2025 Earnings and Strategic Growth Initiatives

C-RAD AB reported a positive earnings trend for the third quarter of 2025, with a 12% increase in revenue and a 19% EBIT margin, driven by strong demand for their SGRT solutions and significant growth in their services sector. Despite geopolitical uncertainties affecting sales processes, the company is taking proactive steps to strengthen its market presence, with notable growth in the EMEA region and strategic partnerships aimed at enhancing patient safety in radiotherapy.

The most recent analyst rating on ($SE:CRAD.B) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on C-Rad AB Class B stock, see the SE:CRAD.B Stock Forecast page.

C-RAD Announces Leadership Transition with New Acting CEO

C-RAD has announced a leadership change with CEO Cecilia de Leeuw stepping down and CFO Linda Frölén taking over as acting CEO. Johan Danielsson has been appointed deputy CEO, and board member Peter Simonsbacka will consult to boost activity levels. The company is actively recruiting a new CEO. This transition aims to maintain the company’s momentum in the market, particularly in enhancing the quality of life for cancer patients through their SGRT technology.

The most recent analyst rating on ($SE:CRAD.B) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on C-Rad AB Class B stock, see the SE:CRAD.B Stock Forecast page.

C-RAD Expedites Q3 2025 Interim Report Approval

C-RAD has announced an advancement in the approval process for its interim report for the third quarter of 2025, following recent management changes. The board meeting to approve the report has been moved up, with distribution planned for October 21, 2025, and an investor presentation scheduled for October 23, 2025, indicating proactive steps in company operations and communication with stakeholders.

The most recent analyst rating on ($SE:CRAD.B) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on C-Rad AB Class B stock, see the SE:CRAD.B Stock Forecast page.

C-RAD to Present Q3 2025 Interim Report

C-RAD AB announced it will release its interim report for the third quarter of 2025 on October 23. The company will host a presentation on the same day, led by CEO Cecilia de Leeuw and CFO Linda Frölén, to discuss the report and answer questions. This event provides stakeholders with insights into C-RAD’s financial performance and strategic direction.

The most recent analyst rating on ($SE:CRAD.B) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on C-Rad AB Class B stock, see the SE:CRAD.B Stock Forecast page.